Výsledky vyhledávání - "Peter A. D'Arienzo"

Comparison of fluoroquinolone kinetics of kill in susceptible and resistant Gram-positive conjunctival pathogens

Autor: Peter A. D'Arienzo, Rudolph S Wagner, Joseph J. Dajcs, Tiffany Jamison, Belinda Bell, David W. Stroman

Publikováno v: Advances in Therapy. 27:39-47

The purpose of this study was to compare moxifloxacin's rate of kill of susceptible and resistant Gram-positive organisms with that of ciprofloxacin and ofloxacin, using concentrations found in human conjunctiva after instillation of one drop.Staphyl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8bd574b3206e7d022929a330895d7a6
https://doi.org/10.1007/s12325-010-0004-y

Zobrazit plný text záznamu

Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study

Autor: Arthur B. Epstein, Ira Finegold, Peter A. D'Arienzo, David B. Granet

Publikováno v: Clinical therapeutics. 28(10)

Objectives: This post hoc analysis used data from a previous study to more precisely evaluate the efficacy of olopatadine hydrochloride and epinastine hydrochloride in alleviating various levels of severity of ocular itching and conjunctival redness

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ee03600bd951233c3a3199476a57c0
https://pubmed.ncbi.nlm.nih.gov/17157118

Zobrazit plný text záznamu

Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model

Autor: Ira Finegold, Bobby Q. Lanier, Greg L. Ledgerwood, Arthur B. Epstein, David B. Granet, Peter A. D'Arienzo

Publikováno v: Current medical research and opinion. 20(8)

Olopatadine hydrochloride 0.1% ophthalmic solution (Patanol) and epinastine hydrochloride 0.05% ophthalmic solution (Elestat) are two topical antiallergic agents. Olopatadine is indicated for the treatment of the signs and symptoms of allergic conjun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf272fdd803c7dc0de5afc701c2aee6e
https://pubmed.ncbi.nlm.nih.gov/15324525

Zobrazit plný text záznamu

Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge

Autor: Bob Q. Lanier, Martin K. Kägi, Peter A. D'Arienzo, Dennis L. Spangler, Mark B. Abelson, William E. Berger, David B. Granet

Publikováno v: Clinical therapeutics. 24(7)

One approach to treating allergic rhinoconjunctivitis is the concomitant use of an intranasal spray such as fluticasone propionate to alleviate nasal symptoms and a topical or systemic agent to relieve ocular symptoms. It has not yet been determined

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3edd60b2cdd69bc34c1af4f55e616a16
https://pubmed.ncbi.nlm.nih.gov/12182260

Zobrazit plný text záznamu

Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model

Autor: Andrea Leonardi, George Bensch, Peter A. D'Arienzo

Publikováno v: Clinical therapeutics. 24(3)

Emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution are 2 topical antiallergic agents available in the United States and other countries. Emedastine is indicated for the temporary relief of the signs and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef178de5045a71b2ed9905da10accb6
https://pubmed.ncbi.nlm.nih.gov/11952024

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání